Drugs / SapRNA™-MICA/B Tumor Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06610227 | Nov 2024 → Sep 2025 overdue | cancer | NING LI | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SapRNA-MICA/B Tumor Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06610227 ↗ |
| Known as | SapRNA-MICA/B | “monotherapy with SapRNA™-MICA/B Tumor Vaccine, which will be administered by intramuscular injection” NCT06610227 ↗ |
| Modality | Vaccine | “RNA Tumor Vaccine Targeting MICA/B Stress Proteins” NCT06610227 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT06610227 ↗ |
| Target | MICA | “RNA Tumor Vaccine Targeting MICA/B Stress Proteins” NCT06610227 ↗ |